Top Industry Leaders in the Anti Neoplastic Agents Market
Latest Anti-Neoplastic Agents Companies Updates
Roche Holding AG (Switzerland) Secured an FDA breakthrough designation for its investigational bispecific T-cell engager, Tecentriq-Polatuzumab vedotin, for the treatment of triple-negative breast cancer (Jan 2024).
AstraZeneca PLC (UK) Announced positive Phase 3 data for its TROPION™ (durvalumab) in combination with tremelimumab for the treatment of unresectable Stage III non-small cell lung cancer (Dec 2023).
Bristol-Myers Squibb Company (US) Received FDA approval for its Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) for the treatment of first-line advanced esophageal squamous cell carcinoma (Dec 2023).
Merck & Co., Inc. (US) Initiated Phase 3 trial for its investigational KRAS G12C inhibitor, AMG 598, for the treatment of non-small cell lung cancer (Jan 2024).BeiGene Ltd. (China): Entered into a strategic partnership with Novartis to co-develop and commercialize BeiGene's investigational anti-PD-1 antibody tislelizumab for global markets (Dec 2023).
List of Anti-Neoplastic Agents Key companies in the market:
- Amgen Inc.
- Boehringer Ingelheim GmbH
- Oxford BioTherapeutics Ltd.
- Bayer AG
- Aspen Holdings
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Baxter Healthcare Corporation